Happy Thanksgiving Eve, Pharmalittle readers. This is Allison, filling in for Mr. Pharmalot. I recently hosted a mini Thanksgiving dinner for friends, and was stumped trying to pick music to play in the background. Why aren’t there any real Thanksgiving songs? We have an overabundance of Christmas music. I certainly can’t play Adam Sandler’s Thanksgiving song over and over all night. Please reach out if you have any music suggestions! This newsletter, and Ed, will be back in your inbox Monday morning. Now onto the news. …
The Trump administration on Tuesday evening unveiled the prices for 15 drugs that were the subject of Medicare negotiations for the second year, STAT reports. The administration said it saved $8.5 billion, or 36%, compared to what it would’ve paid last year had the negotiated prices been in effect. The negotiated-price drugs include Novo Nordisk’s semaglutide, sold under the brands Ozempic and Rybelsus for diabetes and Wegovy for weight loss and cardiovascular risk prevention.
As the U.S. Food and Drug Administration’s Commissioner’s National Priority Voucher program has picked up steam, questions and criticisms about the initiative have been building beyond biopharma, Fierce Biotech details. With a letter to Commissioner Marty Makary, Democratic New Jersey Rep. Frank Pallone Jr. and Independent Vermont Sen. Bernie Sanders shared “deep concerns” about the program, noting that it has not received congressional authorization.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
